'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 5, 1996, Pages 1945-1954

  Cunningham, D ^a   Zalcberg, J R ^b   Rath, U ^c   Olver, I ^d   Van Cutsem, E ^e   Svensson, C ^f   Seitz, J F ^g   Harper, P ^h   Kerr, D ⁱ   Perez Manga, G ^j   Azab, M ^k   Seymour, L ^k   Lowery, K ^k  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f STOCKHOLM SÖDER HOSPITAL   (Sweden)

^g INSTITUT PAOLI CALMETTES   (France)

^h GUY S HOSPITAL   (United Kingdom)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k Seneca Pharmaceuticals Ltd   (United Kingdom)

more..

Author keywords

Advanced colorectal cancer; Chemotherapy; Colorectal cancer; Palliation; Phase III study; Thymidylate synthase inhibitor; Tomudex

Indexed keywords

EID: 33947153048     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)88251-7     Document Type: Article

References (33)

1. Moller Jenson O, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990, 26, 1167-1256.
2. Boring C, Squires TS, Tong T, Montgomery S. Cancer Statistics Ca 1994, 44, 7-26.
3. Chu CK, Tarone RE, Chow W-H, et al. Temporal patterns in colorectal cancer incidence, survival and mortality from 1950 through 1990. J Natl Cancer Inst 1994, 86, 997-1006.
4. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1407-1418.
5. Erlichman C, Fine S, Wong A, Elhakim T. A randomised trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988, 6, 469-475.
6. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
7. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomised comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12, 14-20.
8. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994, 330, 1136-1141.
9. Herrmann R. Systemic treatment of colorectal cancer. Eur J Cancer 1993, 29A, 583-586.
10. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9, 1967-1972.
11. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomised trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus methotrexate in previously untreated patients with advanced colorectal cancer. J Clin Oncol 1987, 5, 1559-1565.
12. Petrelli N, Douglas HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic advanced colorectal cancer: a prospective randomised Phase III trial. J Clin Oncol 1989, 7, 1419-1426.
13. Doroshow JH, Multhauf P, Leang L, et al. Prospective randomised comparison of fluorouracil versus fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990, 8, 491-501.
14. Labianca R, Pancera G, Aitini, et al. Folinic acid and 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for Study of Digestive Tract Cancer). Ann Oncol 1991, 2, 673-679.
15. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthease inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991, 51, 5579-5586.
16. Clarke JS, Ward J, De Boer M, et al. Phase I study of the new thymidylate synthase inhibitor Tomudex' (ZD1694) in advanced malignancy. Ann Oncol 1994, 5, Suppl 5, 132 Abs 240. 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy.
17. Cunningham D, Zalcberg J, Smith IE, et al. 'Tomudex': a novel thymidylate synthase (TS) inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 1994, 5, Suppl 8, 179 Abs 0904.
18. Zalcberg J, Schornagel JH, Cunningham D, et al. Tomudex (ZD1694) a new specific TS inhibitor has substantial activity in colorectal cancer. 1st Int. Congr. From Gene to Cure; Colorectal Cancer 1995; Abs P64. IKA 15th Anniversity International Congress, 9-11 February 1995.
19. Commission of the European Communities. Good Clinical Practice for Trials on Medicinal Products in the European Community, 1991.
20. World Health Organisation. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO offset Publications 1979, No. 48.
21. Hayward JL, Carbone PP, Henson JC, et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977, 13, 89-94.
22. Wittes RE, ed. Manual of Oncologic Therapeutics. Philadelphia, J.B. Lippincott, 1989/1990.
23. Aaronson NK, Ahmedazi S, Bergamot B, et al. The European Organisation for Research & Treatment of Cancer QIQ - C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-376.
24. Stangl R, Attendorf-Hofmann A, Charnley RM, Scheale J. Factors influencing the natural history of liver metastases. Lancet 1994, 343, 1405-1410.
25. Graf W, Bergstrom R, Pahlman L, Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 1994, 13, 89-94.
26. Scheithauer W, Rosen H, Kornek G-V, Sebasta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993, 306, 752-755.
27. Stein B, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 1995, 75, 11-17.
28. Clarke SJ, Jackman AL, Judson IR. The history of the development and clinical use of CB3717 and ICI D1694. In YM Rustum, ed. Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. New York, Plenum Press, 1993, 277-287.
29. Jackman AL, Gibson W, Brown M, et al. The role of the reduced-folate carrier and metabolism in intracellular polyglutamates for the activity of ICI D1694. In YM Rustum, ed. Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. New York, Plenum Press, 1993, 265-276.
30. Kochwa W. 5-Fluourouracil (5FU) plus interferon alpha-2a (Roferon-A) vs 5FU plus leucovorin (LV) in metastatic colorectal cancer. Results of a multicentre, multinational Phase III study. Proc Am Soc Clin Oncol 1993, 12, 562.
31. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: a randomised trial of the Northern Californian Oncology Group. J Clin Oncol 1989, 7, 1427-1436.
32. Jodrell DI, Murray LS, Reed NS, Canney PA, Kaye SB, Cassidy J. Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? Br J Cancer 1994, 70, 749-752.
33. Valsecchi R, Labianca R, Cascinu S, et al. High dose (HD) versus low dose (LD) L-leucovorin (LLV) as a modulation of 5-days 5-fluorouracil in advanced colorectal cancer (ACC): A "GISCAD" ASCO 1995, 14, 457.